The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance

扩大的伙伴关系将使Alnylam和Medison能够在一个全球联盟下帮助加速多个地区的患者进入

Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies

Medison是多区域合作伙伴类别的创始人和领导者，将利用其独特的统一平台，将Alnylam的创新RNAi技术有效地全球商业化

ZUG, Switzerland, April 30, 2024 /PRNewswire/ -- Medison Pharma ('Medison'), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets..

瑞士祖格，2024年4月30日/PRNewswire/--Medison Pharma（“Medison”）是一家专注于为国际市场的患者提供高度创新疗法的全球制药公司，而领先的RNAi治疗公司Alnylam Pharmaceuticals，Inc.（纳斯达克：ALNY）今天宣布，将进一步扩大其在中东欧和以色列的现有合作伙伴关系，以包括拉丁美洲和亚太地区的选定市场以及其他国际市场。。

Medison, the creator and leader of the multi-regional partnership category, has established a unique, unified commercialization platform in international markets, particularly for the treatment of rare and severe diseases. Medison is the only partner that focuses solely on the most innovative therapies..

Medison是多区域合作伙伴类别的创始人和领导者，在国际市场上建立了一个独特、统一的商业化平台，特别是用于治疗罕见和严重疾病。Medison是唯一专注于最具创新性疗法的合作伙伴。。

Alnylam and Medison initially partnered in 2018. Ever since, the partnership has expanded to additional regions and markets, to ensure that Alnylam's commercial therapies, such as ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) are made available across multiple international markets..

Alnylam和Medison最初于2018年合作。自那时以来，该合作伙伴关系已扩展到其他地区和市场，以确保Alnylam的商业疗法，如ONPATTRO®（patisiran），AMVUTTRA®（vutrisiran），GIVLAARI®（givosiran）和OXLUMO®（lumasiran）可在多个国际市场上获得。。

'We are delighted to extend yet again our existing partnership with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in additional APAC and LATAM markets,' said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam.

Alnylam高级副总裁兼合作伙伴和新兴市场负责人诺顿·奥利维拉（Norton Oliveira）说：“我们很高兴再次扩大与Medison的现有合作伙伴关系，这将使我们能够增强我们的影响力，并将Alnylam创新RNAi疗法的益处带给其他亚太和拉美市场的患者。”。

'Medison is at the forefront of the global trend of consolidating international markets under one alliance. Together, we'll provide faster access to more patients around the world.'.

“麦迪逊在巩固国际市场的全球趋势中处于领先地位。我们将共同为世界各地的更多患者提供更快的服务。”。

'The new category of the multi-regional partnerships that we have been creating in the past few years continues to get traction with the most innovative biotech companies,' said Meir Jakobsohn, Founder and Executive Chairman of Medison. 'We are proud of our longstanding partnership with Alnylam and will continue to work together to bridge geographical gaps, ensuring that Alnylam's life-saving therapies reach patients in need.'.

麦迪逊公司创始人兼执行董事长迈尔·雅各布森（MeirJakobsohn）说，我们在过去几年中建立的新型多区域合作伙伴关系继续吸引着最具创新性的生物技术公司我们为与Alnylam的长期合作关系感到骄傲，并将继续共同努力弥合地理差距，确保Alnylam的救生疗法能够惠及有需要的患者。”。

'Our unified commercial platform enables biotech companies to transform numerous complex and fragmented markets and regions into a unified territory, and we are proudly leading the trend and the category,' said Gil Gurfinkel, CEO of Medison. 'Our expanding partnership with Alnylam shows just how our one-of-a-kind unified commercial platform, with single alliance management across multiple markets and regions, is of great value to leading biotech companies.

麦迪逊首席执行官吉尔·古芬克尔（GilGurfinkel）说：“我们的统一商业平台使生物技术公司能够将众多复杂而分散的市场和地区转变为一个统一的领域，我们自豪地引领这一趋势和类别。”我们与Alnylam不断扩大的合作关系表明，我们独一无二的统一商业平台，跨多个市场和地区的单一联盟管理，对领先的生物技术公司具有巨大价值。

This partnership will make Alnylam's therapies available in additional international markets, offering newfound hope for patients suffering from rare diseases.'.

这种合作关系将使Alnylam的疗法在其他国际市场上可用，为患有罕见疾病的患者提供新的希望。”。

About RNAi

关于RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine.

RNAi（RNA干扰）是一种基因沉默的自然细胞过程，代表了当今生物学和药物开发中最有前途和快速发展的前沿之一。它的发现被誉为“每十年左右发生一次的重大科学突破”，并获得2006年诺贝尔生理学或医学奖的认可。

By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made.

通过利用我们细胞中发生的RNAi的自然生物学过程，一类被称为RNAi疗法的新型药物现已成为现实。小干扰RNA（siRNA）是介导RNAi并构成Alnylam RNAi治疗平台的分子，它通过有效沉默信使RNA（mRNA）（编码致病或疾病途径蛋白的遗传前体）而在当今药物的上游发挥作用，从而阻止了它们的产生。

This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases..

这是一种革命性的方法，有可能改变遗传病和其他疾病患者的护理方式。。

About Medison Pharma

关于Medison Pharma

Medison is a global pharma company focused on providing access to highly innovative therapies to patients in international markets, with presence in Central and Eastern Europe, Canada, Latin America, Asia Pacific, Australia and Israel. Medison is the first to create an international commercialization platform for highly innovative therapies, helping to save and improve lives by making the best available novel treatments accessible to patients in international markets.

Medison是一家全球性制药公司，专注于为国际市场的患者提供高度创新的治疗方法，业务遍及中欧和东欧、加拿大、拉丁美洲、亚太地区、澳大利亚和以色列。Medison是第一家为高度创新疗法创建国际商业化平台的公司，通过向国际市场上的患者提供最佳可用的新型治疗方法，帮助挽救和改善生命。

Medison has a track record of multi-regional partnerships with leading pharmaceutical and biotech companies seeking to expand their global reach..

Medison与领先的制药和生物技术公司建立了多区域合作伙伴关系，以扩大其全球影响力。。

To learn more visit www.medisonpharma.com.

To learn more visit www.medisonpharma.com.

About Alnylam Pharmaceuticals

关于Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines.

Alnylam Pharmaceuticals（纳斯达克：ALNY）已将RNA干扰（RNAi）转化为一类全新的创新药物，有可能改变患有罕见和流行疾病且需求未得到满足的人的生活。基于诺贝尔奖获得者的科学，RNAi疗法代表了一种强大的，临床验证的方法，产生了转化药物。

Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis.

自20年前成立以来，Alnylam领导了RNAi革命，并继续实现将科学可能性变为现实的大胆愿景。Alnylam的商业RNAi治疗产品有ONPATTRO®（patisiran）、GIVLAARI®（givosiran）、OXLUMO®（lumasiran）、AMVUTTRA®（vutrisiran）和Leqvio®（inclisiran），这些产品正在由Alnylam的合作伙伴诺华开发和商业化。

Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.

Alnylam拥有丰富的研究药物渠道，包括处于后期开发阶段的多种候选产品。Alnylam正在实施其“Alnylam P5x25”战略，通过可持续创新和卓越的财务表现，为世界各地的罕见病和常见病患者提供变革性药物，从而产生领先的生物技术概况。

Alnylam is headquartered in Cambridge, MA..

Alnylam总部位于马萨诸塞州剑桥市。。

Logo: https://mma.prnewswire.com/media/2391475/Medison_Pharma_and_Alnylam_Logo.jpg

标志https://mma.prnewswire.com/media/2391475/Medison_Pharma_and_Alnylam_Logo.jpg

Contacts:

联系人：

Medison Pharma

Medison Pharma

Inbal Chen, Corporate Communications

Inbal Chen，企业传播

T: +972-54-4400784

T： 电话：972-54-4400784

E: inbalc@medisonpharma.com

Einbalc@medisonpharma.com

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Sara Guzzone Fallon, Senior Director, Global Commercial Communications

Sara Guzzone Fallon，全球商业传播高级总监

T: +1 631 335 1379

T： +1 631 335 1379

E: sfallon@alnylam.com

Esfallon@alnylam.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/medison-pharma-and-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-partnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in-additional-latam-and-apac-markets-including-australia-302131423.html.

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/medison-pharma-and-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-partnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in-additional-latam-and-apac-markets-including-australia-302131423.html.

SOURCE Medison Pharma; Alnylam Pharmaceuticals

SOURCE Medison Pharma；Alnylam Pharmaceuticals

Company Codes: NASDAQ-NMS:ALNY

公司代码：NASDAQ-NMS：ALNY